GlassScriptPhysician profile
Brittany Lamboy
NPI 1023619970
$1,711.10
in general payments reported to CMS, 2019-2025
21 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $43.04 · 2023: $603 · 2024: $416 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.61 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $229.37 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $224.19 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $176.58 | 2021-2025 | Libtayo |
| Leo Pharma INC. | $135.50 | 2023-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $122.76 | 2023-2025 | Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $108.96 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $101.96 | 2023-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $95.36 | 2024-2025 | |
| Organon LLC | $75.05 | 2024-2025 | Hadlima, Vtama |
| Incyte Corporation | $74.27 | 2023-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Arcutis Biotherapeutics, INC. | $48.73 | 2024 | Zoryve |
| Genzyme Corporation | $40.41 | 2025 | |
| Amgen INC. | $37.96 | 2025 | Otezla |
| Pfizer INC. | $35.23 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $34.44 | 2023-2024 | Bimzelx |
| Galderma Laboratories, L.P. | $31.12 | 2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $26.70 | 2024 | Vtama |
| Botanix Sb INC | $19.00 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $18.39 | 2025 | Valchlor |
| Kyowa Kirin, INC. | $15.13 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Lamboy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.